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Abstract This article, based on ethnographic research conducted in a major Italian
institution specialising in cancer care and research, provides insight into the clinical and
basic research laboratory practices articulated around an experimental protocol designed to
develop a biomarker. The article adopts an ‘ecological’ perspective matured in the ﬁeld of
science and technology studies of the translational process and suggests that biomedical
activities are multi-directional, and cannot be understood in reductionist terms, that is, as a
two-way linear transfer of bio-knowledge from the bench to bedside and back. I propose the
notion of technomimicry, in its dual acceptation in the clinical and experimental sense, to
understand the cognitive, social and material strategies involved in the circuit of migration
of heterogeneous materials and information across scientiﬁc laboratories and clinics. Clinical
and experimental technomimicry theoretically capture the multi-directional and multi-modal
process of the re-location of materials and bio-knowledge from one site to another. These
concepts also highlight how the epistemological boundaries of the clinic and laboratory are
required to be mutually adjusted and continuously realigned in order to translate laboratory
facts into clinical activities, and clinical evidence into researchable issues.
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Introduction
Contemporary life sciences are increasingly marked by the ‘translational impera-
tive’ (Fischer, 2012; Rose, 2013; Lewis et al, 2014), which implies a close
proximity between research and development (R&D) activities and clinical
practice through the two-way transfer of information, materials and knowledge
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between scientiﬁc laboratories and clinical settings. This close relationship
implies the possibility for the latter to foster exploration of new scientiﬁc issues
(Zerhouni, 2007; Goldblatt and Lee, 2010; Evans and Scarbrough, 2014).
Both on the policy level and in scientiﬁc debates, support for this research
model has been increasingly justiﬁed through the argument that substantial
investments of material and ﬁnancial resources in basic laboratory research,
while contributing to major scientiﬁc discoveries, have not immediately
produced the expected new therapeutic and diagnostic devices or new life
technologies that could signiﬁcantly reduce the incidence of certain diseases in
terms of morbidity and mortality (Perlstadt, 2009). From a scientiﬁc perspec-
tive, this argument has been justiﬁed by claiming the weakness of experiment-
ing on animal models for the production of clinically relevant evidence
(Contopoulos-Ioannidis et al, 2003; Butler, 2008; Shanks et al, 2009). From a
socio-organisational perspective, some authors have insisted that the main
factors hampering the construction of epistemological and institutional dialo-
gue between bench and bedside are the divergent objectives, role expectations
and different professional cultures that characterise physicians and scientists.
(Hallowell et al, 2009a).
Conceptually speaking, translational research circumscribes an approach
oriented to enhance the transformation of scientiﬁc evidences constructed in
laboratories into new clinically actionable patient treatment protocols and
technologies (Brown, 2007). Therefore, new research and funding pro-
grammes have revived the rhetoric of ‘unity between care and scientiﬁc
research’ in order to develop treatments that are more effective, less invasive
and personalised to the patient’s genetic proﬁle (Jones et al, 2011; Cox and
Webster, 2013).
Assuming a sociological perspective, translational biomedicine brings a
number of relevant issues pertaining to new conﬁgurations of disciplinary
epistemologies, medical and scientiﬁc practices, and institutional arrangements
to the attention of social studies of health and medicine (Cambrosio et al, 2006a;
Wainwright et al, 2009; Cambrosio et al, 2012).
This article contributes to the on-going debate on the emergence of transla-
tional biomedicine by presenting data collected through ethnographic research
conducted in a major Italian institution specialising in cancer care and research.
The article focuses on the research and clinical practices articulated around an
experimental protocol designed to develop a biomarker, which is a new clinical
utility to support the personalisation of treatments for patients suffering from
colorectal cancer. In particular, it pays special attention to how the patient’s body
is elaborated and re-conﬁgured as an ‘experimental subject’. I argue that the
experimental subject is constructed through an ensemble of sociomaterial
practices – as an expression of the mutual entanglements between social actors
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and technologies (Orlikowski, 2007) – which imply the coordination and
epistemological congruence between laboratories and clinical settings.
The activities rooted in translational science and devoted to the development
of biomarkers for personalised medicine are multi-directional and cannot be
understood in reductionist terms: as merely the two-way linear transfer of bio-
knowledge from the bench to bedside and back. The concept of technomimicry,
in both the clinical and experimental sense, is crucial here. Clinical and
experimental technomimicry, considered together, constitute a useful conceptual
device to understand the cognitive, social and material strategies involved in the
circulation of heterogeneous materials and information across scientiﬁc labora-
tories and clinics.
Clinical technomimicry highlights how the laboratory itself can be re-framed
and adjusted to render laboratory facts and scientiﬁc phenomena congruent with
the processes of care and the clinical management of patients. Similarly,
experimental technomimicry helps to understand how the clinic itself can be re-
framed as a research site where patients are enroled not only for care, but also as
participants in biomedical research activities. In this sense, clinical and experi-
mental technomimicry theoretically capture the multi-directional and multi-
modal process of re-locating materials and bio-knowledge from one site to
another. They also highlight how the epistemological boundaries of the clinic
and laboratory are required to be mutually adjusted and continuously re-aligned
in order to translate laboratory facts into clinical activities, and clinical evidences
into researchable issues.
Scientiﬁc Background: Translations, Bodies, Biomarkers, and
Personalised Treatments
Recent achievements by the Human Genome Project have led to changes
in the way biomedical research and clinical practice are conceived and
conducted. New alignments between ‘normal’ and ‘pathological’ (Keating and
Cambrosio, 2003; Miller et al, 2006) have emerged and are redeﬁning the overall
scope of ‘post-genomics’.
One of the major spin-offs concerning translational biomedicine is ‘pharmaco-
genomics’, which has become signiﬁcant in molecular oncology and promises a
new era in personalised medicine (Hedgecoe, 2004; Ginsburg andWillard, 2009).
Personalised medicine identiﬁes a speciﬁc segment of translational biomedicine
that opens up new clinical strategies in the treatment of patients since it
combines traditional drug administration evaluation factors (such as age, body
mass index and sex) with the patient’s genetic proﬁle (Basik et al, 2011).
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In molecular oncology, a growing number of medical institutions specialising
in cancer care and research on both sides of the Atlantic have pursued new
research programmes focusing on treatment personalisation (Webster et al,
2004; Keating and Cambrosio, 2012). The main objective of these research
programmes is to identify, quantify and validate speciﬁc molecular devices
(called biomarkers), which allow cancer patients to be stratiﬁed according to
their genomic proﬁle in order to design more effective clinical treatments (Kohli-
Laven et al, 2011). Therefore, biomarkers may be clinically utilised to categorise
and classify persons within sub-molecular populations who differ in their
susceptibility to a particular disease or their response to a speciﬁc therapeutic
compound (Tutton, 2012).
In analytical terms, biomarker development requires an extensive human
molecular categorisation process. It is a medical-scientiﬁc activity of distin-
guishing, labelling and categorising biological phenomena by classes or
categories (Bowker and Star, 1999). This means that a human subject is
represented by a discrete and objectiﬁed genetic characteristic (such as a gene
or protein) that may help predict the likely response to a speciﬁc drug. For this
reason, biomarkers are not simply tools used for allocating human subjects to a
set of predeﬁned epidemiological labels but are also devices for naming and
identifying speciﬁc patterns of inter-variable bio-physiological characteristics
in the human genome.
Currently, identifying and validating biomarkers represents an area of great
sociological interest for analysing production processes and materialisation of
biomedical knowledge (Löwy, 2000; Lock, 2007). Despite the key role played
by personalised medicine, social sciences have not fully explored biomarker
discovery and validation. Instead, the vast majority of contributions have
focused on genetic discrimination (Kahn, 2004, 2010; Abu El-Haj, 2007;
Fitzgerald, 2014); the relationship between biomarkers and processes of
patient subjectiﬁcation (Rosser, 2000; Clarke and James, 2003; Clarke et al,
2009); and the importance of biomarkers in the management of biomedical
risk and ambiguity in diagnostic decision making (Fosket, 2004, 2009; Sulik,
2009; Lock, 2013).
Notably, these works have largely omitted the practices of design and
development of new molecular devices and have taken for granted the embedded
technoscientiﬁc dimension. Theoretically, therefore, it would be useful to investi-
gate the way in which patients, physicians, biological samples and researchers
(supported by a number of technological devices) shape cooperative strategies to
drive translational processes of knowledge across bench and bedside.
These cooperative strategies are articulated through practices allowing the
conversion and abstraction of ‘life in itself’ into information (Clarke et al, 2010).
I suggest that there are three main different levels of abstraction of the materiality
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of the living body in information: (i) in vivo, in the form of direct intervention on
the organism; (ii) in vitro, in the form of a biological sample; and (iii) in silico, as
a form of computer-assisted elaboration of data and information. These three
levels constitute the technoscientiﬁc modalities of producing knowledge in
contemporary biomedicine (Thacker, 2005).
The next section outlines the theoretical framework elaborated to grasp the
process of biomarker construction as an emerging outcome by the ecology of
interactions between heterogeneous social actors, medical and scientiﬁc knowl-
edge, and technologies.
Theoretical considerations
Facing the emergence of translational biomedicine, the most recent contributions
arising from the dialogue between science and technology studies (STS) and
social studies of health and medicine (Keating and Cambrosio, 2003; Atkinson
et al, 2007; Epstein, 2007) suggest that the on-going reconﬁguring of disciplinary
epistemologies, biomedical work and institutional arrangements must be under-
stood by starting from practices where scientiﬁc and clinical knowledge,
standards, protocols and technological devices are related to each other through
a relationship of mutual generation (Latimer et al, 2006; Cambrosio et al, 2009;
Moreira, 2012).
A number of ethnographic studies in the ﬁeld of STS have been conducted in
research laboratories and have explored the social and technical dimensions of
daily scientiﬁc activities (Latour and Woolgar, 1979; Knorr-Cetina, 1981; Lynch,
1985). Referring to the theoretical reﬂections surfaced by laboratory studies, STS
invite to focus the analytical gaze not only on discursive practices or human
interactions but also on the widespread network of relationships between human
and non-human entities. Thus, this theoretical tradition emphasises the agency
of heterogeneous materials (such as symbols, technologies and artefacts) that
contribute, along with human subjects, to the construction of collective action
and everyday life (Law, 2010).
Social sciences, paralleling laboratory studies, have a long tradition of
qualitative research on the practical dimension of clinical medicine (Berg,
1992, 1997; Atkinson, 1995; Timmermans and Berg, 2003; Mol et al, 2010).
However only a few contributions have explored the recurring interactions
between the laboratory, bench and clinic (Löwy, 1996; Quirke and Gaudillière,
2008). Traditionally, scientiﬁc research and clinical practices have been
understood to be profoundly different, and sometimes conﬂicting, activities
because of their different epistemological, cultural and ethical orientations
(Morgan et al, 2011). Although scientists and physicians are conceptually and
theoretically associated with different professional communities (Snow, 1993)
and epistemic cultures (Knorr-Cetina, 1999), the issue of boundaries and
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demarcations (Gieryn, 1983, 1995) between scientiﬁc research and clinical
practice seems to be overshadowed by the changes triggered by translational
biomedicine and the scientiﬁc discourses mobilised in supporting it. In fact,
the most interesting issue raised by personalised medicine is the central
position that the patient’s living body and its biomedical trajectory (in terms
of information, biological material and clinical evidence) has assumed not only
within activities exclusively concerned with care but also as a constitutive
(and non-residual) element in scientiﬁc research.
Recent literature on translational research has addressed the issue of epistemic
coordination between laboratory and clinic by framing translational biomedicine
as promissory science, emphasising the performativity of technoscientiﬁc expec-
tations in mediating laboratory and clinical practices (Wainwright et al, 2006;
Martin et al, 2008; Brosnan and Michael, 2014; Crabu, 2014a).
Given this state of affairs, this article takes a different analytical approach
towards translational biomedicine. I adopt an ‘ecological’ perspective rooted in
social studies of the translational process (Star and Griesemer, 1989; Fujimura,
1995; Suchman, 2000) in order to investigate the sociomaterial relationships by
which physicians, scientists and patients develop convergence strategies to
support the circulation of materials and knowledge across research laboratories
and clinical settings. Speciﬁcally, an ‘ecological’ sensitivity allows to take into
account the ‘distributed agency’ (Star, 1989) between human subjects and non-
human objects and the processual construction of their mutual interdependence.
According to this ecological perspective, the concept of social action is not centred
on an interpretative model, which sees human actors as the unique and dominant
agent that organises social life, but instead emphasises the materiality of the
context and the mutual relations, changes, and negotiations through which social
actors, together with technological objects, elaborate the social order.
The present article attempts to follow this theoretical perspective by exploring
how personalised medicine – as a speciﬁc subﬁeld of translational biomedicine –
and related technologies (for example, biomarkers) emerge through a dialogue
between heterogeneous actors, expert knowledge, materials and technological
devices that are extremely diversiﬁed and belong to domains, which are
commonly considered as distinct ﬁelds of scientiﬁc and epistemological work
(Lewis et al, 2014).
After presenting the empirical context and related methodology, the following
sections will analyse empirical data in relation to the outlined theoretical
framework. It will discuss, therefore, the concepts of clinical and experimental
technomimicry as they pertain to the process of shaping the epistemological
congruence between clinic and laboratory. The aim is to capture the socio-
material practices of the translation of materials and knowledge between these
two sites in order to build a biomarker as a new clinically actionable technology.
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Methodology
Empirical ﬁeld
Personalised medicine has played a central role in redeﬁning cancer treatment
and research practices. The ﬁeld of oncology has recently increased efforts to
deﬁne a number of therapeutic options for the personalisation of care. For this
reason, as pointed out by previous studies, personalisation of care represents
an emblematic context for gaining insight into translational biomedicine
(Cambrosio et al, 2006b; Keating and Cambrosio, 2012).
The empirical material discussed here was collected through ethnographic
research conducted by the author in a department of clinical and experimental
pharmacology (which will be referred to by the pseudonym ‘Human_Ph@rma’)
hosted by a major biomedical institute in Northern Italy specialising in cancer
care and research. The department was carefully selected following several in-
depth conversations with the scientiﬁc director and other key informants. The
ethnographic research was carried out 4 days a week for a period of 6 months.
Human_Ph@rma is dedicated to conducting investigations in the pharmacoge-
nomics ﬁeld to determine the best way to utilise genetic information to personalise
cancer therapy. The department’s director has a strong international reputation in
this research area. The laboratory team – including molecular biologists, pharma-
cologists, chemists, data managers and medical laboratory scientiﬁc ofﬁcers –
contributed, with the support of clinicians and research nurses, to the study of a
single nucleotide polymorphism (a DNA sequence variation) of the gene
‘UGT1A1’. From early descriptive studies, the UGT1A1 gene polymorphism has
been a promising research object for translational biomedicine with the aim to
personalising treatment for patients suffering from colorectal cancer.
When the ethnographic research was carried out, Human_Ph@rma’s research-
ers were working on a research protocol devoted to validating the UGT1A1 gene
polymorphism as a biomarker that would stratify colorectal cancer patients based
on their likely response to chemotherapy by identifying a ‘treatment-resistant’
population (that can receive a higher dose of the drug) and a ‘sensitive’ or
‘mutated’ population (for whom the prescribed dose will be lower).
The ethnographic investigation focused mainly on the ensemble of socio-
material practices articulated around this experimental protocol in order to
reconstruct how personalised medicine is acted within an ecology of actions
involving the patient’s body, biomedical technologies, scientiﬁc knowledge and
healthcare professionals.
The ethnographic method allows to perform the main methodological principle
arising by the ecological perspective, or rather of directly following human and
non-human actors and their actions (Star, 1999). In this way, both contextual and
emergent entities involved in the ‘local articulation’ of the research protocol
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(Crabu, 2014b), and that therefore contribute to the construction of the biomarker,
are taken into account. In other words, ethnography inspired by an ecological
sensitivity allows the exploration of the distributed agency and the mutual
entanglements among human subjects and technical objects at stake in the
mediation between laboratory and clinical practices (Star, 1999).
Data collection
Empirical data were primarily collected through the ethnographic observation of
daily activities within laboratories and hospital wards. The observations closely
followed all the Human_Ph@rma staff (three molecular biologists, two pharmacol-
ogists, two research nurses, one data manager, one clinician and one laboratory
scientiﬁc ofﬁcer) involved in a range of different protocol-related activities. Subse-
quently, 10 in-depth interviews were conducted with the scientiﬁc director and all
the Human_Ph@rma staff. Participants gave consent for the interviews to be audio
recorded; interviews were transcribed using the verbatim method. Finally, other
Human_Ph@rma institutional documents such as the informed consent form, the
form for clinical data collection, the experimental protocol and other informational
materials relating to the management of the enroled patients were also consulted.
Analysis
Field notes and interviews transcriptions were coded using Atlas.ti software and
followed constructivist grounded theory principles (Charmaz, 2009). Adopting a
grounded theory data coding process allowed descriptive labels to emerge at an
early stage. Subsequently, this coding process was accompanied by the develop-
ment of theoretical labels, which were guided by an ecological perspective to
social phenomena.
Findings
Enroling the patients: conﬁguring the ‘in vitro’ experimental subject
The potential patient (x) to be included in the protocol is normally selected
by the physician, who starts the procedure [by] obtaining the informed
consent by the patient. I normally give them oral and written information so
that they can read it carefully at home and, when they come back, they can
decide whether to participate in the study or not. In the meantime, we start
with the patient screening, staging, monitoring, etc. [INT._1, data manager]
According to the protocol, the clinician is responsible for identifying potential
human subjects for recruitment. Patients, by providing their ‘biological self’,
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represent the key actors for the implementation of R&D activities localised
between the clinic and the laboratory.
During experimental subject enrolment, the patient may physically enter
Human_Ph@rma premises, answer a short questionnaire on general health
conditions, consent to biometric and clinical tests, and provide biological
samples. At this stage, informed consent plays an essential role: it is a device
through which patients are formally conﬁgured as ‘experimental subjects’ that
are aware that they are giving access to their biological self not only for
therapeutic purposes but also for research objectives.
Patients selected for the experimental study donate a blood sample in order to
assess and identify the genetic variation of the UGT1A1 gene polymorphism,
which is responsible for metabolising a speciﬁc chemotherapy drug in colorectal
cancer treatment:
In the bioanalytical laboratory, I meet Maria [lab scientiﬁc ofﬁcer]. She is
working on a set of biological samples. Maria explains to me: ‘You know, it
is the same old story here! I need to do this genetic analysis. I’m processing
the samples to analyse [the] “UGT” gene and its polymorphism. This helps
us understand if the patient can be enrolled in the experimental protocol.
As a rule, we use the extractor to extract DNA from the patient’s blood. For
[the] “UGT” polymorphism, there is an initial sequencing for assigning a
molecular weight to your genetic material, and then you check if the
mutation takes place’. [ethnographic ﬁeld notes]
For patients included in the experimental study, the ‘molecular make-up’
involves a set of technologies and tools that transform and abstract a biological
sample into genetic information. This activity manipulates in vitro blood samples
in order to ‘extract’ and ‘produce’ patient-speciﬁc bio-knowledge relating to its
own DNA. Here, the main disciplinary ﬁeld is molecular biology, which activates a
bio-molecular representation of the patient in terms of genes and polymorphisms
speciﬁc to those genes. If the ‘genotyping’ excludes the mutation of UGT1A1 gene
polymorphism, the patient may be included in the experimental protocol and
receive a speciﬁc chemotherapy regimen. The genotyping of the patient – achieved
using a standardised technology for molecular measurement (Derksen, 2000;
Keating and Cambrosio, 2005) – enables the production of genetic parameters
related to the speciﬁc molecular condition of the patient. This practice bestows
‘genuine plasticity’ on the sample (Taussig et al, 2013): biological material
extracted from the patient is transformed into something completely different and
immaterial (that is, genetic variables) but at the same time is able to represent the
patient itself.
The in vitro activities at Human_Ph@rma, however, are not limited to patient
genotyping. The enroled patient – through the material mediation of blood
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plasma samples – crosses the boundaries of the laboratory after chemotherapy
cycles administered in hospital:
As you can see, plasma sampling is scheduled at speciﬁc times. What I do
is quantify the drug and its metabolites within the samples and determine
their concentration. […] In practical terms, I need to determine the
concentrations of a given drug and its metabolites, which I then relate
to time. On the basis of the concentration-time ratio, I use dedicated
software to investigate all the pharmacokinetic properties of the
compound, such as half-life values. In short, I assess drug metabolism.
[INT._2, pharmacologist]
This excerpt highlights how the experimental subjects, through the research
activities conducted on their biological samples, are easily mobilised, transported
and rendered biologically intelligible in order to facilitate their migration from
care to biomedical research. After the administration of the therapeutic com-
pound and through the analysis of biological samples, the patient is represented
by a set of drug metabolites. Producing an ensemble of biological parameters
related to the metabolic processes of the patient, which is carried out using a
speciﬁc technology for molecular quantiﬁcation and standardised procedures
(Keating and Cambrosio, 2003), transmutes the patient’s sample into a bio-
informational representation of his/her living body for developing a laboratory
facts relevant for clinical care.
Moving from molecular biology to pharmacokinetics, next pharmacologists try
to assess how a known bio-molecular condition – in this case, the absence of a
mutation in the ‘UGT’ gene – may affect drug concentration and its metabolisa-
tion in the patient’s body.
Overall, these laboratory activities conﬁgure the patient into a mere
biological resource responsible for drug metabolism. According to Rose
(2007), technologies for decomposing, manipulating and quantifying vitality
at the molecular level enable ‘the fragmentation of the body into transferable
tissues which could, often with difﬁculty, be freed from their marks of origin
and re-utilised in other bodies’ (p. 14). By resorting to a speciﬁc technology for
molecular quantiﬁcation, the transformation of the biological sample into
abstract biomedical information – or rather representing the patient solely in
terms of a genetic variation responsible for drug metabolisation and metabo-
lites – ruptures the speciﬁc afﬁnity and idiosyncratic liaison between the
individual patient and his/her biological sample and between the biological
sample and the speciﬁc pathological singularities affecting it. For this reason,
in vitro activities are oriented towards the biological samples in order to get
information about the drug and its metabolism, rather than towards the
relationship between the patient and the pathological condition.
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In general, the centrality of the patient’s living body recalls the methodological
foundation of translational biomedicine, which is based on the assumption that
using biological materials extracted from human beings should enable the
production of knowledge and tools that may have an immediate and direct
relevance on care practices:
[…] even when you do experiments, you will always try to get the most
reliable and accurate results, as accurate as possible, because the data that
you are producing will have an impact on the patient: this is what
translational research is all about. This means that if you are analysing
samples for the ﬁrst time, you should always work in pairs, as you do
in diagnostics. It is about patients, and you just can’t get it wrong.
[INT._3, laboratory technician – emphasis mine]
Handling in vitro biological samples focuses on the level of DNA and its
variations, generating a source of knowledge and information to support the
therapeutic intervention on the patient. Molecular biology, along with studies on
drug metabolism, is oriented towards generating abstract information from the
biological sample so that biomedical knowledge can be extended to a plurality
of subjects categorised under the same molecular classiﬁcation. In this sense,
the scientiﬁc practices conducted on the biological samples are carried out in
accordance with a number of procedures and adjustments that may help build
reliable and clinically relevant evidence. For this reason, researchers tend to refer
to clinical diagnostic routines as a repertoire of standardised activities that are
sufﬁciently stable and reliable to be re-adapted and re-located into research
laboratories. In this way, laboratory practices reduce a metabolic condition into
quantitative biological variables that can be measured, thus allowing their
migration to the clinic.
This multi-directional translation process implies an epistemological border-
crossing between the clinic and laboratory research. In our example, the
technological devices for molecular measurement and quantiﬁcation shape a
process of epistemological border-crossing of both bio-knowledge and biological
material, enabling laboratory evidence to be translated into clinically actionable
knowledge (Wainwright et al, 2006). This process can be expressed as clinical
technomimicry: the set of sociomaterial practices distributed in the laboratory
which shape the epistemological congruence between scientiﬁc research and
clinical action (Lewis et al, 2014). This process occurs through a set of cognitive,
material and technological resources performed by bio-researchers to accomplish
the daily scientiﬁc work of analysing biological samples inside laboratory spaces.
Theoretically, the concept of clinical technomimicry may help understand the
relationship between research and clinic by focusing on the sociomaterial
practices allowing laboratory science to incorporate clinical needs in its logic of
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action and relocating laboratory evidence into clinically actionable knowledge
that allows intervention in the patient’s biomedicalisation trajectory.
Working ‘in vivo’: Body, molecules, and hospital wards
The previous section exploring laboratory practices showed how the relationship
between the body and pathology is subsumed into abstract bio-molecular
information pertaining to human metabolism of a chemotherapeutic compound.
Contextually, the living body is also concerned with in vivo clinical work, which
centres on the pathological dimension and its progression. Here, the patient is
conﬁgured and represented as a biological resource that carries a speciﬁc disease.
In vivo practices aim to validate a speciﬁc gene polymorphism as a ‘druggable’
biomarker relevant to the personalisation of clinical care:
We are evaluating how certain polymorphisms of “UGT” allow treatment
with higher doses of the drug because they show a lower toxicity and a better
clinical response. […] Patients are treated with different doses depending on
their body surface and genotype. The amount of the drug should be assessed
by a physician. […] At each treatment cycle, the clinician must decide
whether we can proceed or not. [INT._2, pharmacologist]
Working in vivo requires research nurses, pharmacologists and medical
oncologists to perform practices directly on the patient’s body within the
hospital. At this stage, the experimental subject receives drug infusion, blood
testing, and monitoring of biochemical and physiological parameters to deter-
mine how their genetic proﬁle may impact the correlation between chemother-
apy and disease regression. The amount of drugs to be administered is gradually
increased until the maximum dose tolerated by the patient has been identiﬁed.
It is clear that a patient included in an experimental protocol should receive
further monitoring compared to other patients. […] With this type of
patient, you have to be much more accurate even on the clinical level. For
example, if CAT [Computed Axial Tomography] is to be performed every
two months, after two months and one day a CAT scan must be done.
I mean, in a normal routine, if you do it after a week, it doesn’t make much
difference. Even if you do it after one month. However, when it comes to
experimental protocols, you need to be as accurate as possible, especially
with the sampling, because these data and samples will also be used by the
laboratory researchers working downstairs. [INT._4, oncologist]
The ‘molecular gaze’ (Rose, 2001) (extended to the experimental subject
through laboratory activities) is juxtaposed with the ‘clinical gaze’ (Foucault,
1994) (aimed at evaluating the course of the disease in relation to chemother-
apy). Physicians are responsible for collecting clinical data on the patient while
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administrating the therapeutic compound. Clinical oncology employs a number
of monitoring activities – such as bio-physiological and blood chemistry
information and CAT scans to evaluate tumour lesions – in order to represent
the living body in term of a composite set of clinical records. The oncologist’s
emphasis on compliance with formal protocol requirements is also of particular
interest for understanding the multi-localised and multi-disciplinary manage-
ment of the experimental subject. During the ethnographic investigation, the
timely implementation of the protocol (for example, the timing of examination
and sampling procedures) was one of the main concerns expressed by
the operators involved in the experimentation. In clinical routine, for the sole
purpose of therapeutic relevance, it is possible for the oncologist to exercise
discretion in the timing of patient monitoring. However, traditional physician
autonomy in clinical patient management (Allsop and Mulcahy, 1996) ceases
when the patient’s treatment is also intended for data collection aimed at
articulating experimental protocols across bench and bedside.
In translational research, the clinic is not a place where biomedical knowl-
edge is exclusively ‘consumed’ to heal a patient (van den Hoonaard, 2009).
Rather, clinical settings are reframed to advance scientiﬁc research. Here, an
ensemble of procedures oriented towards producing scientiﬁc data and
biological samples are re-located from the laboratory to the clinic in order to
generate information and biological material epistemologically consistent with
research laboratory needs.
Although physicians can assume that analyses conducted on a patient with a
month’s delay may not affect the management of cancer care, the coordination of
scientiﬁc protocols with related experimental subjects requires coordination
between clinicians and researchers. The clinical gaze must comply with
standardised laboratory procedures so that the data obtained are epistemologi-
cally reliable for research purposes.
The process of coordinating between clinical gaze and laboratory procedures
can be conceptualised by the notion of experimental technomimicry. This
concept refers to how the clinic re-adapts its routines and care practices to
establish epistemological congruence with the research laboratory’s rules and
methodological conventions. This process occurs when a research protocol is
translated into the clinic, changing working medical practices in order to align
the care setting to the laboratory research model. The concept particularly
captures the multi-modal practices involved in translating clinical signs and
symptoms into researchable issues or in a set of ‘doable’ scientiﬁc phenomena
(Fujimura, 1987). As Clarke and colleagues have demonstrated (2010), in
contemporary biomedicine, patients are increasingly involved in a range of
research activities that may go beyond the requirements of a single therapeutic
project. In this sense, the notion of experimental technomimicry undermines the
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traditional dichotomy between the laboratory and the clinic and highlights how
laboratory practices may shape the biomedicalisation experience.
Working ‘in silico’: Locating bio-representations in biomarkers
During clinical and experimental activities, the medical and scientiﬁc staff
construct and collect a large amount of molecular and clinical information
concerning the experimental subject’s biomedicalisation trajectory. The patient’s
body is engaged at different levels in these activities and is represented by a set of
discrete elements (speciﬁc to the biomedical disciplines involved in the protocol)
aimed at biomarker validation.
In this cross-laboratory scenario, an additional aspect of in vivo and in vitro
activities is centralised electronic data management. The information derived
from the patient’s body and biological samples is recorded on paper forms which
are then re-processed in silico with IT tools:
When medical visits, therapy, and pharmacokinetics have been completed,
you should try to retrieve all the information available, including examina-
tions performed, medical visits, and so on. […] To do this, we use CRFs
[Case Report Form]. CRFs arise from a “fanciful” approach, and then we
rely on the professional experience gained over the years. […] You would
try to get the most relevant information out of each form and summarise it
into the CRF that in your opinion is the most appropriate. Then, of course,
we require the help of those who can extract data with statistical software
to ﬁnd the information that we are looking for. [INT._1, data manager]
The transformation of a genetic variation into a ‘druggable’ biomarker requires
accurate management and data analysis throughout the entire experimental
process and involves a diverse range of human actors, technologies, and
biological entities. Generally, the CRFs provide an important tool for organising
and managing clinical and biological information through which the patient’s
living body takes on an immaterial informational status.
In analytical terms, CRFs allow the research team to arrange a set of patient
bio-representations and identify the patient as a statistical unit composed of a
number of variables, such as nominal variable (sex, type of disease, peculiarities
of the genetic proﬁle), ordinal variable (staging of the disease) and cardinal
variable (weight, number of polymorphonuclear leucocytes).
According to Lionelli (2012), digitally managing bio-data and building data-
bases play a central role in contemporary biomedicine by fostering the interface
of clinical and biological knowledge and thus supporting translational medicine
into shaping new care options.
During in silico activities, the main disciplinary ﬁeld is halfway between infor-
mation science and biostatistics, which denotes the disciplinary infrastructure
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where biological information about the patients is processed into alphanumeric
strings and submitted for analysis.
Reducing the experimental human subject to a statistical unit is a process of
abstraction where different multi-representations of the patient (as a longitudinal
expression of his/her biomedicalisation trajectory) are isolated, processed and
analysed within in silico contexts unrelated to the organism from which they
were obtained. Using a statistical algorithm for assessing the correlation between
genetic variation and clinical response to drug treatment suspends any simila-
rities between the human subject and the related idiosyncratic medical/scientiﬁc
information. In this way, the molecular and clinical representation of the
patient’s body may be reduced to an informative dimension no longer related to
a speciﬁc patient. Thus, a genetic variation pertaining to a single body is
conﬁgured into a ‘druggable’ biomarker that may be extended to other persons,
thus providing a new therapeutic option.
As Nelson and colleagues have highlighted (2013), biomarker validation
involves the transformation of a genetic variation into a single, clinically
actionable, biological entity. This entity deﬁnes a new molecular class based on
genetic variation by incorporating the knowledge obtained from the interfacing
between clinic and laboratory. In this respect, through the notion of technomi-
micry – which put into light the ‘heterogeneous engineering’ (Law, 1987) of
cognitive, material and social resources – it has been possible to theoretically
capture the production of a new clinical tool that can be re-located from one
organism to another, and can help categorise all the patients affected by a speciﬁc
disease (colorectal cancer in this case) in relation to their genetic proﬁle.
Discussion and Final Considerations
First, this article examined the variety of practices that are differently localised
between the laboratory and the clinic. Then it focused on how the growing
connections between patients’ living bodies and biomedical innovation pro-
cesses may reﬂect the breakdown, erosion and redeﬁnition of the traditional
boundaries between the patient’s status as an object of research and an object of
care, as well as between clinical practice and scientiﬁc research. Indeed, multiple
works describe these processes as constituent elements of the main historical
evolution of western biomedicine, which is based on the production of evidence
through inter-laboratory studies (Cambrosio et al, 2006a).
Since the seminal text of Canguilhem (1989), social studies of health and
medicine have emphasised the need to understand biomedicine considering the
clinic in relation to the processes of scientiﬁc research (Keating and Cambrosio,
2003). These works have revealed how the alignment between normal and
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pathological, or between health and disease, is shaped at the interface between
laboratory and clinic, or between medicine and biology (Löwy, 1996).
This article explored the often-neglected sociomaterial practices by which the
epistemic relations between these two domains are generated. In particular, I
stressed how biomedical knowledge emerging from the laboratory and therapeu-
tic practices are mutually reconﬁgured, deﬁning the ‘biomedical space’ of trans-
lational research for the development of personalised treatments. The concepts
of clinical technomimicry and experimental technomimicry were introduced to
aid the investigation of the multi-dimensional relations between the scientiﬁc
and medical levels, and may be useful for understanding the biomedical
translational process. These process are conceptualised as the emerging outcome
of an ensemble of sociomaterial practices whose main objective involves con-
ﬁguring patients as ‘experimental subjects’ in order to extract scientiﬁc knowl-
edge that may potentially generate new therapeutic options.
From a theoretical standpoint, technomimicry represents a conceptual device
for emphasising the sociomaterial practices through which life-related knowl-
edge can be translated into therapeutic options through in vivo, in vitro and in
silico activities. Further, technomimicry provides an account of translational
research in the making, or a description of how information about biological
processes is incorporated into material devices, thereby translating new institu-
tional models of care and research into practice.
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